Loader

Pathways

PathWhiz ID Pathway Meta Data

PW122417

Pw122417 View Pathway
metabolic

PRPP Biosynthesis

Saccharomyces cerevisiae
The biosynthesis of phosphoribosyl pyrophosphate begins with a product of the pentose phosphate, D-ribose 5-phosphate interact with a phosphopentomutase resulting in a Ribose 1-phosphate or it can be phosphorylated through an ATP driven ribose-phosphate diphosphokinase resulting in a release of a hydrogen ion, an AMP and a phosphoribosyl pyrophosphate. The latter compound is then involved in the purine nucleotides de novo biosynthesis pathway. Ribose 1-phosphate can interact spontaneously with ATP resulting in a release of hydrogen ion, ADP and a ribose 1,5-biphosphate. The latter compound is then phosphorylated through a ribose 1,5-bisphosphokinase resulting in the release of ADP and phosphoribosyl pyrophosphate. The latter compound is then involved in the purine nucleotides de novo biosynthesis pathway.

PW128663

Pw128663 View Pathway
drug action

Prucalopride Action Pathway

Homo sapiens
Prucalopride acts as a selective stimulator of the 5-HT4 receptors while having no interaction with hERG channel or 5-HT1 receptors which reduces significantly the cardiovascular risk found in other similar drugs. 5-HT4 receptors can be found throughout the gastrointestinal tract primarily in smooth muscle cells, enterochromaffin cells, and myenteric plexus. Its activation produces the release of acetylcholine which is the major excitatory neurotransmitter in the GI tract. Hence, prucalopride stimulates motility by interacting specifically with 5-HT4 receptors in the GI tract which causes a release of acetylcholine and further contraction of the muscle layer of the colon and relaxation of the circular muscle layer leading to the propulsion of luminal content. Prucalopride is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

PW145717

Pw145717 View Pathway
drug action

Prucalopride Drug Metabolism Action Pathway

Homo sapiens

PW124237

Pw124237 View Pathway
metabolic

Prueba

Homo sapiens
Prueba de la prueba de la prueba

PW124244

Pw124244 View Pathway
metabolic

Prueba 2

Homo sapiens

PW124320

Pw124320 View Pathway
metabolic

prueba 50000

Homo sapiens

PW124161

Pw124161 View Pathway
disease

prueba1111

Homo sapiens

PW125983

Pw125983 View Pathway
metabolic

Prunasin and Amygdalin Biosynthesis

Arabidopsis thaliana
Prunasin and amygdalin are cyanogenic glucosides, chemical compounds that can release toxic hydrogen cyanide after animal ingestion as a chemical defence. These compounds are also responsible for the bitter taste in many seeds, such as almonds, peaches or apples. Prunasin is transformed into amygdalin during fruit ripening. Cyanogenic glycosides are typically derived from amino acids, such as phenylalanine. This pathway involves the conversion of phenylalanine into prunasin and amygdalin by the enzyme L-phenylalanine N-monooxygenase (CYP79A2) and some other enzymes in the Arabidopsis thaliana species

PW132249

Pw132249 View Pathway
metabolic

Prussian blue Drug Metabolism

Homo sapiens
Prussian blue is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Prussian blue passes through the liver and is then excreted from the body mainly through the kidney.

PW145791

Pw145791 View Pathway
drug action

Prussian blue Drug Metabolism Action Pathway

Homo sapiens